Olaparib

Generic Name: Olaparib

Brand Names: Lynparza

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃FN_₄O_₃

CAS Number: 763113-22-0

Unique Ingredient Identifier: WOH1JD9AR8

Background: Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...

Indication: Ovarian cancer

Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions: Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer

Associated Therapies: Maintenance therapy

Clinical Trials

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Olaparib
Drug: Cediranib

First Posted Date: 2015-01-16

Last Posted Date: 2018-06-12

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 4

Registration Number: NCT02340611

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Trial of Olaparib in Combination With AZD5363 (ComPAKT)

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: olaparib
Drug: AZD5363

First Posted Date: 2015-01-14

Last Posted Date: 2020-02-05

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 60

Registration Number: NCT02338622

Locations: 🇬🇧
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇬🇧
Northern Institute for Cancer, Freeman Hospital, Newcastle, Newcastle upon Tyne, United Kingdom

Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Olaparib
Drug: Degarelix

First Posted Date: 2014-12-24

Last Posted Date: 2019-08-29

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 20

Registration Number: NCT02324998

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge University Hospitals Foundation Trust,, Cambridge, Cambridgeshire, United Kingdom

Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer

Phase 1

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Olaparib
Drug: Cisplatin
Radiation: IMRT

First Posted Date: 2014-12-04

Last Posted Date: 2024-05-08

Lead Sponsor: University College, London

Target Recruit Count: 70

Registration Number: NCT02308072

Locations: 🇬🇧
Velindre Cancer Centre, Wales, United Kingdom
🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

First Posted Date: 2014-11-24

Last Posted Date: 2024-01-10

Lead Sponsor: UNICANCER

Target Recruit Count: 1460

Registration Number: NCT02299999

Locations: 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
Hopitaux Du Leman, Thonon-les-Bains, France

and more 21 locations